FLC testing in multiple myeloma and kidney disease: An American Perspective

Multiple myeloma (MM) is one of the most common blood cancers, often involving impaired kidney function. Free light chains (FLC) testing is a guideline-recommended cornerstone in the diagnosis, monitoring, and disease management of MM. This session explores the current role of FLC testing in MM, and considers the influence of kidney function on FLC test result. Dr. Zaydman shares an American perspective on this important subject.

Mark Zaydman, Washington University Phycisians

Dr. Mark Zaydman
Department of Pathology and Immunology
Division of Laboratory and Genomic Medicine
Washington University Physicians, USA